Circulation Reports
Online ISSN : 2434-0790
Volume 2 , Issue 7
Showing 1-10 articles out of 10 articles from the selected issue
Original Articles
Arrhythmia/Electrophysiology
  • Keitaro Senoo, Tomonori Miki, Takashi Okura, Hirokazu Shiraishi, Takes ...
    Type: ORIGINAL ARTICLE
    Subject area: Arrhythmia/Electrophysiology
    2020 Volume 2 Issue 7 Pages 345-350
    Published: July 10, 2020
    Released: July 10, 2020
    [Advance publication] Released: May 27, 2020
    JOURNALS OPEN ACCESS FULL-TEXT HTML

    Background:Hypertension in patients with atrial fibrillation (AF) is a known independent risk factor for stroke. The Complete blood pressure (BP) monitor (Omron Healthcare, Kyoto, Japan) was developed as the first BP monitor with electrocardiogram (ECG) capability in a single device to simultaneously monitor ECG and BP readings. This study investigated whether the Complete can accurately differentiate sinus rhythm (SR) from AF during BP measurement.

    Methods and Results:Fifty-six consecutive patients with persistent AF admitted for catheter ablation were enrolled in the study (mean age 65.8 years; 83.9% male). In all patients, 12-lead ECGs and simultaneous Complete recordings were acquired before and after ablation. The Complete interpretations were compared with physician-reviewed ECGs, whereas Complete recordings were reviewed by cardiologists in a blinded manner and compared with ECG interpretations. Sensitivity, specificity, and κ coefficient were also determined. In all, 164 Complete and ECG recordings were simultaneously acquired from the 56 patients. After excluding unclassified recordings, the Complete automated algorithm performed well, with 100% sensitivity, 86% specificity, and a κ coefficient of 0.87 compared with physician-interpreted ECGs. Physician-interpreted Complete recordings performed well, with 99% sensitivity, 85% specificity, and a κ coefficient of 0.85 compared with physician-interpreted ECGs.

    Conclusions:The Complete, which combines BP and ECG monitoring, can accurately differentiate SR from AF during BP measurement.

Health Services and Outcomes Research
  • Yoshito Kadoya, Masahiko Hara, Kosuke Takahari, Yoko Ishida, Masatake ...
    Type: ORIGINAL ARTICLE
    Subject area: Health Services and Outcomes Research
    2020 Volume 2 Issue 7 Pages 351-356
    Published: July 10, 2020
    Released: July 10, 2020
    [Advance publication] Released: June 03, 2020
    JOURNALS OPEN ACCESS FULL-TEXT HTML

    Background:The Japanese Ministry of Health, Labour and Welfare has tried to promote telemedicine since 2018, but faces difficulties in increasing the use of telemedicine partly due to a lack of clinical evidence. This study investigated the disease control status and safety of telemedicine, which, in Japan, is provided under the National Health Insurance system, for the treatment of lifestyle diseases under the present legal restraints.

    Methods and Results:This multicenter prospective observational study started in April 2018 and enrolled 34 patients with lifestyle diseases, including hypertension, dyslipidemia, and diabetes. Primary and secondary outcome measures included control status, serial changes in clinical indices, and the safety of telemedicine 6 months after implementation. Control status was assessed by the attending physician, and differences in blood pressure (BP), low density lipoprotein cholesterol (LDL-C), or HbA1c levels were evaluated. Of the 34 patients, 29 were successfully introduced to telemedicine and followed-up for 6 months. Median patient age was 77 years, 14 (48.3%) were men, 24 (82.8%) had hypertension, 17 (58.6%) had dyslipidemia, and 9 (31.0%) had diabetes. At the 6-month follow-up, no patients had experienced exacerbation of underlying diseases, with no significant changes in BP, LDL-C, or HbA1c. Moreover, no telemedicine-associated adverse events were observed.

    Conclusions:Telemedicine can be a safe and feasible option for managing lifestyle diseases under the present legal restraints.

Heart Failure
  • Hajime Kataoka
    Type: ORIGINAL ARTICLE
    Subject area: Heart Failure
    2020 Volume 2 Issue 7 Pages 357-363
    Published: July 10, 2020
    Released: July 10, 2020
    [Advance publication] Released: June 02, 2020
    JOURNALS OPEN ACCESS FULL-TEXT HTML

    Background:There is scant clinical data of electrolyte analyses in the pleural fluid under heart failure (HF) pathophysiology.

    Methods and Results:This study retrospectively analyzed data from 17 consecutive patients who presented with pleural effusion and underwent thoracentesis. A diagnosis of worsening HF was established by clinical criteria (presentation, echocardiography, serum B-type natriuretic peptide, and response to therapy). Samples of non-heparinized pleural fluid and peripheral venous blood, obtained within 2 h of each other, were subjected to biochemical analysis. The source of pleural effusion was determined as transudate or exudate according to Light’s criteria. Fifteen patients (53% men; mean [±SD] age 85±11 years) had HF-associated pleural effusion, 10 of whom had transudative effusion and 5 who had exudative effusion (fulfilling only 1 [n=4] or both [n=1] lactate dehydrogenase criteria). The effusion-serum gradient (calculated by subtracting the serum electrolyte concentration from the effusion electrolyte concentration) was significantly higher for chloride (mean [±SD] 7.4±2.6 mEq/L; range 4–14 mEq/L) than sodium (0.9±1.4 mEq/L; ranging from −1 to 4 mEq/L) and potassium (−0.1±0.3 mEq/L; ranging from −0.8 to 0.2 mEq/L; P<0.001 for each).

    Conclusions:In HF-associated pleural effusion, the chloride concentration is higher in the pleural effusion than the serum, indicating that chloride may have an important role in the formation and retention of body fluid in the pleural space.

Imaging
  • Hitoshi Matsuo, Tomohiro Kawasaki, Tetsuya Amano, Yoshiaki Kawase, Yos ...
    Type: ORIGINAL ARTICLE
    Subject area: Imaging
    2020 Volume 2 Issue 7 Pages 364-371
    Published: July 10, 2020
    Released: July 10, 2020
    [Advance publication] Released: June 05, 2020
    JOURNALS OPEN ACCESS FULL-TEXT HTML

    Background:Coronary computed tomography angiography (CCTA)-derived fractional flow reserve (FFRCT) is an established tool for identifying lesion-specific ischemia that is now approved for use by the Japanese insurance system. However, current clinical reimbursement is strictly limited to institutions with designated appropriate use criteria (AUC). This study assessed differences in physicians’ behavior (e.g., use and interpretation of FFRCT, final management) according to Japanese AUC and non-AUC site designation.

    Methods and Results:Of 5,083 patients in the ADVANCE Registry, 1,829 from Japan were enrolled in this study. Physicians’ behavior after interrogating CCTA and FFRCTwas analyzed separately according to AUC and non-AUC site designation. Compared with AUC sites, patients referred for FFRCTfrom non-AUC sites had a higher rate of negative FFRCT, less severe anatomic stenosis, and a slightly lower rate of management plan reclassification (51.2% vs. 61.3%), with near-identical utility in both groups. Actual care corresponded equally well to post-FFRCTplans in both groups. The likelihood of revascularization for positive or negative FFRCTwas similar between the 2 groups. Importantly, AUC and non-AUC sites were equally unlikely to revascularize patients with negative FFRCTand stenosis >50% or patients with positive FFRCTand stenosis <50%.

    Conclusions:Compared with AUC sites, non-AUC sites had lower disease burden and reclassification of management plans, but nearly identical clinical integration. Actual care corresponded equally well to post-FFRCTrecommendations at both sites.

Pulmonary Circulation
  • Kayoko Kubota, Sunao Miyanaga, Noriko Iwatani, Kenjuro Higo, Akihiro T ...
    Type: ORIGINAL ARTICLE
    Subject area: Pulmonary Circulation
    2020 Volume 2 Issue 7 Pages 372-377
    Published: July 10, 2020
    Released: July 10, 2020
    [Advance publication] Released: June 12, 2020
    JOURNALS OPEN ACCESS FULL-TEXT HTML

    Background:The Geriatric Nutritional Risk Index (GNRI) is a simple tool for assessing nutritional risk that predicts prognosis in patients with heart failure. This study evaluated associations between the GNRI at first hospitalization and prognosis in patients with pulmonary artery hypertension (PAH) and those with chronic thromboembolic pulmonary hypertension (CTEPH).

    Methods and Results:This retrospective investigation included 104 patients with either PAH or CTEPH who were treated at Kagoshima University Hospital in Japan. Patients were divided into a high (≥92) and low (<92) GNRI groups. Body mass index and serum albumin levels were significantly lower in the low GNRI group (P<0.001). Over a median follow-up period of 24 months, the incidence of pulmonary hypertension rehospitalization was higher in the low GNRI group (P=0.04). Kaplan-Meier analysis revealed that the cumulative event-free rate was significantly lower in the low GNRI group (P=0.002). Low GNRI was significantly associated with a poorer outcome after adjusting for different sets of confounding factors, including: age and sex (P=0.004); age, sex, and PAH (P=0.043); and age, sex, and mean pulmonary artery pressure (P=0.003).

    Conclusions:The GNRI at first hospitalization is useful for predicting prognosis in PAH and CTEPH patients.

Images in Cardiovascular Medicine
Corrigendum
feedback
Top